HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoji Nagashima Selected Research

Semaphorin-3A

7/2016Caerulein-induced pancreatitis augments the expression and phosphorylation of collapsin response mediator protein 4.
11/2014Collapsin response mediator protein 2 is involved in regulating breast cancer progression.
12/2013Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer.
5/2013Aberrant epidermal expression of semaphorin 3A and nerve growth factor in prurigo nodularis.
1/2013Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis.
9/2012Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin.
1/2011Intranasal administration of semaphorin-3A alleviates sneezing and nasal rubbing in a murine model of allergic rhinitis.
12/2008Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoji Nagashima Research Topics

Disease

111Neoplasms (Cancer)
07/2022 - 02/2002
47Renal Cell Carcinoma (Grawitz Tumor)
03/2022 - 05/2002
23Neoplasm Metastasis (Metastasis)
02/2022 - 04/2002
15Carcinoma (Carcinomatosis)
09/2021 - 09/2004
12Carcinogenesis
08/2021 - 05/2002
11Inflammation (Inflammations)
10/2021 - 03/2005
10Prostatic Neoplasms (Prostate Cancer)
11/2012 - 02/2002
9Kidney Neoplasms (Kidney Cancer)
09/2021 - 04/2005
8Fibrosis (Cirrhosis)
01/2022 - 11/2002
8Pancreatic Neoplasms (Pancreatic Cancer)
09/2017 - 04/2002
6Non-alcoholic Fatty Liver Disease
10/2021 - 09/2009
6Chronic Kidney Failure (Chronic Renal Failure)
06/2021 - 12/2002
6Lung Neoplasms (Lung Cancer)
01/2018 - 04/2002
6Colorectal Neoplasms (Colorectal Cancer)
11/2014 - 03/2002
5Breast Neoplasms (Breast Cancer)
07/2022 - 06/2008
5Adenoma (Adenomas)
01/2020 - 02/2011
5Infections
01/2020 - 01/2005
5Stomach Neoplasms (Stomach Cancer)
10/2017 - 02/2002
5Liver Failure
06/2009 - 01/2005
4Colonic Neoplasms (Colon Cancer)
12/2021 - 04/2002
4Insulin Resistance
10/2021 - 11/2008
4Disease Progression
10/2020 - 01/2006
4Melanoma (Melanoma, Malignant)
07/2019 - 04/2002
4Alcoholic Fatty Liver
02/2017 - 04/2015
4Adenocarcinoma
01/2013 - 06/2002
3Tuberous Sclerosis (Bourneville's Disease)
01/2020 - 01/2009
3Angiomyolipoma
01/2020 - 01/2009
3Glomerulonephritis
01/2019 - 07/2015
3Hypoxia (Hypoxemia)
06/2018 - 02/2005
3Body Weight (Weight, Body)
02/2016 - 01/2002
3Hypertension (High Blood Pressure)
01/2013 - 08/2011
3Pruritus (Itching)
09/2012 - 12/2008
3Lymphatic Metastasis
11/2011 - 09/2004
2Hemorrhage
03/2022 - 08/2011
2Rheumatoid Arthritis
10/2021 - 02/2011
2Liver Cirrhosis (Hepatic Cirrhosis)
10/2021 - 04/2015
2Liver Diseases (Liver Disease)
10/2021 - 01/2017
2Obesity
10/2021 - 01/2017
2Ovarian Neoplasms (Ovarian Cancer)
08/2021 - 09/2011
2Endometriosis
08/2021 - 09/2011
2Hereditary leiomyomatosis and renal cell cancer
01/2021 - 12/2020

Drug/Important Bio-Agent (IBA)

31Proteins (Proteins, Gene)FDA Link
07/2021 - 01/2002
13Messenger RNA (mRNA)IBA
10/2021 - 11/2003
9Biomarkers (Surrogate Marker)IBA
06/2021 - 02/2005
9LipidsIBA
01/2020 - 02/2005
8Semaphorin-3AIBA
07/2016 - 12/2008
6PKC-3 proteinIBA
11/2018 - 09/2009
6ConnexinsIBA
08/2009 - 07/2004
6Heme Oxygenase-1IBA
08/2008 - 01/2002
5Fumarate Hydratase (Fumarase)IBA
01/2021 - 01/2018
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2020 - 02/2002
5Pharmaceutical PreparationsIBA
01/2018 - 09/2007
5Hormones (Hormone)IBA
08/2014 - 02/2002
5Biological ProductsIBA
06/2014 - 06/2004
4Transcription Factors (Transcription Factor)IBA
11/2021 - 10/2008
4Axitinib (AG 013736)IBA
04/2021 - 01/2017
4TOR Serine-Threonine KinasesIBA
10/2020 - 11/2008
4AntibodiesIBA
11/2019 - 09/2008
4Keratins (Keratin)IBA
07/2019 - 09/2008
4Cadherins (E-Cadherin)IBA
09/2016 - 09/2008
4CreatinineIBA
07/2016 - 01/2002
4LigandsIBA
11/2011 - 11/2007
4CytokinesIBA
11/2010 - 11/2002
4Gap Junction beta-1 ProteinIBA
06/2008 - 07/2004
3Small Interfering RNA (siRNA)IBA
07/2022 - 04/2007
3Immune Checkpoint InhibitorsIBA
03/2022 - 11/2018
3NivolumabIBA
09/2021 - 11/2018
3EnzymesIBA
07/2021 - 09/2016
3Tyrosine Kinase InhibitorsIBA
06/2021 - 11/2003
3Capsules (Microcapsules)IBA
01/2021 - 08/2011
3MucinsIBA
10/2020 - 01/2015
3trans-sodium crocetinate (crocetin)IBA
01/2020 - 01/2009
3PhosphatidylglycerolsIBA
01/2020 - 04/2012
3Microphthalmia-Associated Transcription FactorIBA
08/2019 - 01/2009
3VimentinIBA
07/2019 - 06/2008
3Cathepsin KIBA
03/2019 - 01/2013
3Cisplatin (Platino)FDA LinkGeneric
11/2018 - 07/2005
3LeptinIBA
10/2011 - 02/2011
3AndrogensIBA
11/2008 - 11/2003
3Proliferating Cell Nuclear Antigen (PCNA)IBA
11/2008 - 01/2005
3Complementary DNA (cDNA)IBA
03/2005 - 11/2002
2Glucose (Dextrose)FDA LinkGeneric
10/2021 - 02/2016
2IpilimumabIBA
09/2021 - 01/2021
2Protein Kinases (Protein Kinase)IBA
07/2021 - 02/2013
2Polytetrafluoroethylene (Teflon)FDA Link
12/2020 - 01/2013
2CalciumIBA
06/2020 - 08/2014

Therapy/Procedure

27Therapeutics
03/2022 - 02/2002
26Nephrectomy
09/2021 - 10/2002
7Hepatectomy
06/2014 - 01/2005
5Immunotherapy
09/2021 - 01/2017
5Transplantation
07/2016 - 10/2006
4Renal Dialysis (Hemodialysis)
01/2020 - 06/2008
4Drug Therapy (Chemotherapy)
11/2018 - 12/2010
3Molecular Targeted Therapy
11/2017 - 01/2017
3Kidney Transplantation
07/2016 - 07/2015
3Oral Administration
05/2012 - 04/2002
3Nephroureterectomy
06/2009 - 09/2008
2Radiotherapy
12/2020 - 12/2010
2Hysterectomy
11/2020 - 08/2015
2Parathyroidectomy
06/2020 - 02/2018